A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. (Q52581706)
Jump to navigation
Jump to search
scientific article published on 30 August 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. |
scientific article published on 30 August 2007 |
Statements
A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. (English)
Francis H Grand
Sameena Iqbal
Lingyan Zhang
Nigel H Russell
Andrew Chase
30 August 2007
35
11
1723-1727